Lyell Immunopharma, Inc. (LYEL)

USD 0.59

(-7.9%)

Market Cap (In USD)

173.8 Million

Revenue (In USD)

130 Thousand

Net Income (In USD)

-234.63 Million

Avg. Volume

799.31 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.5949-3.256
PE
-
EPS
-
Beta Value
-0.483
ISIN
US55083R1041
CUSIP
55083R104
CIK
1806952
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Lynn Seely M.D., Ph.D.
Employee Count
-
Website
https://www.lyell.com
Ipo Date
2021-06-17
Details
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.